0 projects

Date from new to old

BIA-Brukerstyrt innovasjonsarena

LTX-315 increases the clinical outcome of cancer immunotherapy

LTX-315 er et peptid bestående av 9 aminosyrer avledet og modifisert fra det naturlig forekommende peptidet lactoferricin. Når kreftceller utsettes for LTX-315 vil cellemembranen til kreftcellen kollapse, og man får nekrotisk celledød der intracellulære organeller som mitokondrier ødelegges. Dett...

Awarded: NOK 13.8 mill.

Project Period: 2017-2021

Location: Oslo

NAERINGSPH-Nærings-phd

Investigating a New Generation of Oncolytic Peptides as Cancer Immunotherapeutic Agents for Deep-Seated Tumors

Målet ved dette prosjektet har vært å utvikle en eller flere "lead" kandidater som immunterapeutiske onkolytiske molekyler rettet mot solide, dyptsittende, tumorer. Dette ble igangsatt med en stor screening av flere potensielle substanser mot både humane og murine kreftceller, samt normale (non-t...

Awarded: NOK 2.0 mill.

Project Period: 2016-2018

Location: Oslo

EUROSTARS-EUROSTARS

E!9146 LTX-109 for the treatment of diabetic foot infections

Infiserte fotsår er et stort problem for pasienter med diabetes. Slike sår kan utvikle seg til alvorlige og omfattende infeksjoner som kan medføre amputasjon. I dag finnes ingen topiske legemidler for behandling av milde, infiserte sår, så det er et stort medisinsk behov for å utvikle slike legem...

Awarded: NOK 2.8 mill.

Project Period: 2014-2017

Location: Oslo

BIA-Brukerstyrt innovasjonsarena

LTX-315, en ny immunterapi for kreft

Tradisjonell kreftbehandling som kirurgi, cellegift og strålebehandling har potensial til å helbrede eller forlenge overlevelsen for kreftpasienter, men dette er ofte ikke tilfellet. Sykdomstilbakefall, resistens mot terapi og alvorlige bivirkninger representerer de store utfordringene i dagens b...

Awarded: NOK 13.0 mill.

Project Period: 2014-2017

Location: Oslo

PES2020-Prosj.etabl.støtte H2020

LTX-109 for the treatment of diabetic foot infections.

The main deliverable will be to provide solid evidence that there is a potential clinical efficacy of LTX-109 in treating infected diabetic foot ulcers. This will be done through a rigorous, well-designed, randomised controlled clinical trial which will thus comprise the main Work Package. Foll...

Awarded: NOK 0.15 mill.

Project Period: 2013-2014

Location: Oslo

BIOTEK2021-Bioteknologi for verdiskaping

Kinase Modulators from Marine Bioprospecting

Approximately 40% of the population living in Norway today will receive a cancer diagnosis in their lifetime and many will die from their disease. Despite several decades of intensive research efforts, the therapeutic options for treating cancer are still limited to traditional interventions bas...

Awarded: NOK 8.4 mill.

Project Period: 2011-2015

Location: Oslo

NAERINGSPH-Nærings-phd

Immunstimulerende egenskaper til LTX-315

I samarbeid med Lytix Biopharma AS (Lytix) er det ved Universitetet i Tromsø (UiTø) utviklet et kreftmedikament som skal testes i kliniske studier inneværende år. Produktet LTX-315, dreper kreftceller ved å lysere plasmamembranen. LTX-315 er et lite kjemi sk modifisert peptid avledet fra lactofer...

Awarded: NOK 1.6 mill.

Project Period: 2010-2013

Location: Oslo

BIA-Brukerstyrt innovasjonsarena

A novel antimicrobial agent for treatment of infections caused by drug-resistant bacteria, preclinical and early phase clinical studie

The present proposal covers preclinical exploratory and Phase I/IIa development programme of LTX-109. The proposal encompasses our internal development program as well as the establishment and management of external production and development programs. L ytix Biopharma AS develop novel antimicro...

Awarded: NOK 8.3 mill.

Project Period: 2009-2011

Location: Oslo

NAERINGSPH-Nærings-phd

Targeted lytic peptides - a new class of molecules designed for lysis of mitochondria in tumor cells

Despite monumental efforts in finding and developing cures, cancer is still a common and life threatening disease; one in three will get cancer and one in five will die of it. Lytix Biopharma AS is developing drugs for treatment of cancer and infection based on lytic peptides and peptidomimetic...

Awarded: NOK 1.1 mill.

Project Period: 2008-2014

Location: Oslo

FUGE-Funksjonell genomforskn.i Norg

Development of a cancer therapy using lytic peptidomimetics

Lytix Biopharma AS (Lytix) works with small synthetic peptides / peptidomimetica derived from primary amino acid sequences from Lactoferrin and that selectively kills cells by disrupting cell membranes. This application for grant concerns the use of the se peptides within cancer treatment where...

Awarded: NOK 13.3 mill.

Project Period: 2007-2009

Location: Oslo

BIA-Brukerstyrt innovasjonsarena

A novel antimicrobial agent for topical treatment of challenging infections caused by drug-resistant bacteria.

"Once life-saving medicines are increasingly having as little effect as a sugar pill. Since 1970, no new classes of antibacterials have been developed to combat infectious diseases. Microbial resistance to treatment could bring the world back to a pre-an tibiotic age." WHO Report 2000: Overcomi...

Awarded: NOK 8.8 mill.

Project Period: 2006-2009

Location: Oslo